Advisory Board
Arthur Sasahara, MD, Advisor
bio
Arthur Sasahara, MD, Advisor
Dr. Sasahara is Senior Physician, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, and Professor of Medicine, Emeritus, Harvard Medical School, Boston, Massachusetts. Dr. Sasahara is currently Co-Director of the Venous Thromboembolism Research Group at Brigham and Women’s Hospital. He obtained his M.D. from Case Western Reserve University School of Medicine and his Residency in Internal Medicine and Cardiology at Tufts, Harvard, and Yale University hospitals. He held the positions of Chief of Cardiology and Chief of Medicine at the Harvard-affiliated West Roxbury Veterans Affairs Medical Center for almost 30 years, as well as being Professor of Medicine at Harvard Medical School. In 1987, he began a 10 year leave of absence and joined Abbott Laboratories as the first Venture Head, Thrombolysis Research. In 1993, he became Senior Venture Head and in 1995, Senior Medical Consultant, Research and Development, Pharmaceutical Products Division. His major research interests are in the field of thrombolysis, hemostasis, and thrombosis. His publications include approximately 300 scientific papers and 6 books. Dr. Sasahara is a member of the Board of Directors of the North American Thrombosis Forum (NATF).
C. Michael Gibson, M.S., M.D., FACC, Advisor
bio
C. Michael Gibson, M.S., M.D., FACC, Advisor
Dr. Gibson is Chief of Clinical Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Director TIMI Core Laboratories and Data Coordinating Center, Brigham and Women’s Hospital, Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts, USA. Dr. Gibson is an interventional cardiologist and chief of clinical research in the division of cardiology at Harvard’s Beth Israel Deaconess Medical Center. He received his masters and medical degree from the University of Chicago and was an intern, resident, and chief resident at the Brigham and Women’s Hospital, Harvard Medical School. He received his training as an interventional cardiologist and served as director of the Coronary Care Unit at Beth Israel Hospital, Harvard Medical School. In the past, Dr. Gibson served as Chief of Cardiology and Director of Interventional Cardiology at the West Roxbury Veterans Affairs Medical Center, Harvard Medical School. He also served as Vice Chairman of Medicine for clinical research and Director of Invasive Cardiology at Allegheny General Hospital. Finally, he served as Associate Chief of Cardiology, Chief of Interventional Cardiology, and Director of the Cardiac Catheterization Laboratory at University of California, San Francisco. Upon return to Boston he served for a period as Chief Academic Officer at Harvard Clinical Research Institute. Dr. Gibson is a principle investigator of multiple international acute coronary syndrome trials within the Thrombolysis in Myocardial Infarction (TIMI) Study Chairman’s Office. He is director of the TIMI Data Coordinating Center where he oversaw creation of the TIMI database that unifies data from over 15 years of TIMI studies in >75,000 patients at over 800 international centers. He invented the corrected TIMI frame count, an index of epicardial blood flow, and the TIMI myocardial perfusion grade, a measure of myocardial perfusion.
Gregory J. Del Zoppo, MD, Advisor
bio
Gregory J. Del Zoppo, MD, Advisor
Dr. Gregory J. del Zoppo, M.D., Associate Member, Department of Molecular and Experimental Medicine, The Scripps Institute. Dr. del Zoppo received his M.D. from the University of Washington School of Medicine and has been a member of the Division of Hematology/Medical Oncology at Scripps Clinic and Research Foundation since 1983. Dr. del Zoppo serves on the Executive Committees of the International Stroke Society, the Stroke Council, and the American Heart Association. He has published widely on therapeutic interventions for cerebral stroke and is a frequent editorialist for Stroke and Nature Medicine. Dr. del Zoppo is a respected expert in novel stroke therapeutics. His research in experimental models of focal cerebral ischemia has resulted in improved understanding of the role of mechanisms of vascular inflammation injury in cerebral stroke. Dr. del Zoppo has consulted for a variety of pharmaceutical and biotechnology companies including Amgen, Genentech, Biogen, Burroughs Wellcome, SmithKline Beecham, Abbott Laboratories, Boehringer Ingelheim GmbH, and ICOS Corp. Dr. del Zoppo has participated in numerous clinical trials in acute ischemic stroke. He was organizer, principal investigator, and chairman of the Steering Committee for TTATTS; organizer, principal investigator and chairman of the Executive/Steering Committee for PROACT; and member of the Safety committees for ECASS and ECASSII, among others.
Samuel Z. Goldhaber, MD, Advisor
bio
Samuel Z. Goldhaber, MD, Advisor
Samuel Z. Goldhaber is Professor of Medicine at Harvard Medical School. He is a staff cardiologist at Brigham and Women’s Hospital (BWH), in Boston, where he practices general cardiology, attends to patients in the Coronary Care Unit, and oversees the BWH Thromboembolism Consultation Service. Dr Goldhaber is Founder and Director of the Anticoagulation Service at BWH, which cares for about 1,500 patients. He is also Director of the BWH Venous Thromboembolism Research Group. Dr Goldhaber received his AB from Harvard College and his MD from Harvard Medical School. He completed his postgraduate training in internal and cardiovascular medicine at the Peter Bent Brigham Hospital (now BWH). Dr Goldhaber is a member of the Program Organizing Committee for the International Society on Thrombosis and Haemostasis. In 2002, he was appointed to the organization’s Council on Thrombosis and the World Federation of Cardiology. In 2004, he was named the Eberhard Mammen Lecturer in Clinical Coagulation Science.
James E. Muller, M.D., Advisor
bio
James E. Muller, M.D., Advisor
Dr. James E. Muller serves as CEO of InfraReDx, Inc as it conducts its clinical studies and prepares for commercialization. Dr. Muller formerly served as chief of cardiology at the Deaconness Hospital, Harvard Medical School, chief of cardiology and a Professor of Medicine at the University of Kentucky Medical Center and at the Harvard Medical School, where he conducted research for over 25 years on the causes of heart attacks. Dr Muller was involved in the proUrokinase PATENT trial, and with the Framingham Heart Study. In 1994, he introduced the term "vulnerable plaque" to describe those plaques likely to disrupt and cause disease onset. He co-founded InfraReDx in 1998 after a detailed search to find the optimal technology to identify lipid-rich coronary artery plaques. Dr. Muller was one of three American Co-founders of the International Physicians for the Prevention of Nuclear War (IPPNW) the organization awarded the 1985 Nobel Peace Prize.
